In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Silence sets up SAB to strengthen liver pipeline

This article was originally published in Scrip

Executive Summary

RNA interference company Silence Therapeutics has created a scientific advisory board with the appointment of two key opinion leaders in the area of liver diseases, Professors Detlef Schuppan and Massimo Pinzani. Professor Schuppan is a consultant gastroenterologist and hepatologist, director of molecular and translational medicine, and full professor of medicine at Mainz University Medical Centre in Germany. He is also professor of medicine and senior visiting scientist at Harvard Medical School. Professor Pinzani is professor of medicine and gastroenterology at the University of Florence, Italy, and visiting professor in the division of hepatology at Osaka City School of Medicine in Japan.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel